Gene and Cell Therapy – Products

These whitepapers highlight how optimized CRISPR protocols and site-specific knock-in technology can be used to engineer simple or complex genetic modifications in allogenic iPSCs.

Aiming to improve exosome purification process that is currently slowing adoption of promising gene therapies and other new modalities.

Research published in Molecular Cell used INDUCE-seq to identify DNA topology as an important regulator of CRISPR targeting specificity. Peer-reviewed data demonstrates the sensitivity of INDUCE-seq DNA break mapping platform.

Expanded footprint, new capabilities mark IDT’s entrance into CRISPR therapeutics space.

At its Capital Markets Day in Visp (CH), Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Sartorius, has released its first Advanced Flow Cytometry Handbook as a comprehensive digital guide to assays and workflows on the iQue® Advanced High Throughput Flow Cytometry Platform.

This literature review explores the latest in 3D immune cell killing assays for cancer immunotherapy research.

Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin®.

This whitepaper highlights essential factors to consider for the successful manufacturing of gene and cell therapies.

Investment to expand cell line development capabilities and accelerate customer workflows, as part of its diverse and tailored antibody solutions.